Time to Speak Out: Who Will be the Winners and Losers in CIRM's New Priorities?
Decisions likely to be made by September, hearings now underway
Fresh details surfaced over the weekend dealing with the multibillion-dollar priorities of the California stem cell and gene therapy program -- details that will affect research spending on afflictions ranging from stroke to Alzheimer’s.
It all fits in with the new look at the program’s plans to award what the agency describes as its “remaining balance”…
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.